{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:35:08Z","timestamp":1789763708370,"version":"4.0.1"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2013,10,15]],"date-time":"2013-10-15T00:00:00Z","timestamp":1381795200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1038\/nrendo.2013.193","type":"journal-article","created":{"date-parts":[[2013,10,15]],"date-time":"2013-10-15T07:06:12Z","timestamp":1381820772000},"page":"724-734","source":"Crossref","is-referenced-by-count":250,"title":["Diagnosis and management of Graves disease: a global overview"],"prefix":"10.1038","volume":"9","author":[{"given":"Luigi","family":"Bartalena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,15]]},"reference":[{"key":"BFnrendo2013193_CR1","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1056\/NEJMcp0801880","volume":"358","author":"GA Brent","year":"2008","unstructured":"Brent, G. A. Clinical practice. Graves' disease. N. Engl. J. Med. 358, 2594\u20132605 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2013193_CR2","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/cen.12060","volume":"78","author":"H Filipsson Nystrom","year":"2013","unstructured":"Filipsson Nystrom, H., Jansson, S. & Berg, G. Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003\u20132005. Clin. Endocrinol. (Oxf.) 78, 768\u2013776 (2013).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo2013193_CR3","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1056\/NEJM200010263431707","volume":"343","author":"AP Weetman","year":"2000","unstructured":"Weetman, A. P. Graves' disease. N. Engl. J. Med. 343, 1236\u20131248 (2000).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2013193_CR4","first-page":"930","volume":"86","author":"TH Brix","year":"2001","unstructured":"Brix, T. H., Kyvik, K. O., Christensen, K. & Heged\u00fcs, L. Evidence for a major role of heredity in Graves' disease: a population-based study of two Danish twin cohorts. J. Clin. Endocrinol. Metab. 86, 930\u2013934 (2001).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.mce.2010.01.013","volume":"322","author":"OJ Brand","year":"2010","unstructured":"Brand, O. J. & Gough, S. C. L. Genetics of thyroid autoimmunity and the role of the TSHR. Mol. Cell. Endocrinol. 322, 135\u2013143 (2010).","journal-title":"Mol. Cell. Endocrinol."},{"key":"BFnrendo2013193_CR6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s12026-012-8312-8","volume":"54","author":"SA Morshed","year":"2012","unstructured":"Morshed, S. A., Latif, R. & Davies, T. F. Delineating the autoimmune mechanisms in Graves' disease. Immunol. Res. 54, 191\u2013203 (2012).","journal-title":"Immunol. Res."},{"key":"BFnrendo2013193_CR7","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1210\/er.2002-0020","volume":"24","author":"BS Prabhakar","year":"2003","unstructured":"Prabhakar, B. S., Bahn, R. S. & Smith, T. J. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr. Rev. 24, 802\u2013835 (2003).","journal-title":"Endocr. Rev."},{"key":"BFnrendo2013193_CR8","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(11)60782-4","volume":"379","author":"JA Franklyn","year":"2012","unstructured":"Franklyn, J. A. & Boelaert, K. Thyrotoxicosis. Lancet 379, 1155\u20131166 (2012).","journal-title":"Lancet"},{"key":"BFnrendo2013193_CR9","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMcp0806317","volume":"360","author":"L Bartalena","year":"2009","unstructured":"Bartalena, L. & Tanda, M. L. Clinical practice. Graves' ophthalmopathy. N. Engl. J. Med. 360, 994\u20131001 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2013193_CR10","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1210\/jc.2012-3873","volume":"98","author":"ML Tanda","year":"2013","unstructured":"Tanda, M. L.  et al. Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed Graves' hyperthyroidism seen at a single center. J. Clin. Endocrinol. Metab. 98, 1443\u20131449 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR11","first-page":"444","volume":"36","author":"E Piantanida","year":"2013","unstructured":"Piantanida, E., Tanda, M. L., Lai, A., Sassi, L. & Bartalena, L. Prevalence and natural history of Graves' orbitopathy in the XXI century. J. Endocrinol. Invest. 36, 444\u2013449 (2013).","journal-title":"J. Endocrinol. Invest."},{"key":"BFnrendo2013193_CR12","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.beem.2011.10.001","volume":"26","author":"V Fatourechi","year":"2012","unstructured":"Fatourechi, V. Thyroid dermopathy and acropachy. Best Pract. Res. Clin. Endocrinol. Metab. 26, 553\u2013565 (2012).","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR13","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1210\/jc.2009-2495","volume":"95","author":"K Boelaert","year":"2010","unstructured":"Boelaert, K., Torlinska, B., Holder, R. L. & Frannklyn, J. A. Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study. J. Clin. Endocrinol. Metab. 95, 2715\u20132726 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR14","first-page":"168","volume":"21","author":"L Bartalena","year":"2000","unstructured":"Bartalena, L., Pinchera, A. & Marcocci, C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr. Rev. 21, 168\u2013199 (2000).","journal-title":"Endocr. Rev."},{"key":"BFnrendo2013193_CR15","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1210\/jc.2012-2802","volume":"97","author":"HB Burch","year":"2012","unstructured":"Burch, H. B., Burman, K. D. & Cooper, D. S. A 2011 survey of clinical practice patterns in the management of Graves' disease. J. Clin. Endocrinol. Metab. 97, 4549\u20134558 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR16","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1089\/thy.2010.0417","volume":"21","author":"RS Bahn","year":"2011","unstructured":"Bahn, R. S.  et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 21, 593\u2013646 (2011).","journal-title":"Thyroid"},{"key":"BFnrendo2013193_CR17","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1089\/thy.2008.0119","volume":"18","author":"J Yoshimura Noh","year":"2008","unstructured":"Yoshimura Noh, J.  et al. Evaluation of a new rapid and fully automated electroluminescence immunoassay for thyrotropin receptor autoantibodies. Thyroid 18, 1157\u20131164 (2008).","journal-title":"Thyroid"},{"key":"BFnrendo2013193_CR18","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1365-2265.2008.03512.x","volume":"71","author":"M Schott","year":"2009","unstructured":"Schott, M.  et al. Clinical value of the first automated TSH receptor autoantibody assay for the diagnosis of Graves' disease (GD): an international multicentre trial. Clin. Endocrinol. (Oxf.) 71, 566\u2013573 (2009).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo2013193_CR19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cca.2008.11.025","volume":"401","author":"D Hermsen","year":"2009","unstructured":"Hermsen, D.  et al. Technical evaluation of the first fully automated assay for the detection of TSH receptor autoantibodies. Clin. Chim. Acta 401, 84\u201389 (2009).","journal-title":"Clin. Chim. Acta"},{"key":"BFnrendo2013193_CR20","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1210\/jc.2009-2470","volume":"95","author":"SD Lytton","year":"2010","unstructured":"Lytton, S. D.  et al. A novel thyroid-stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy. J. Clin. Endocrinol. Metab. 95, 2123\u20132131 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR21","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1089\/thy.2010.0059","volume":"20","author":"K Kamijo","year":"2010","unstructured":"Kamijo, K., Murayama, H., Uzu, T., Togashi, K. & Kahaly, G. J. A novel bioreporter assay for thyrotropin receptor antibodies using a chimeric thyrotropin receptor (mc4) is more useful in differentiation of Graves' disease from painless thyroiditis than conventional thyrotropin-stimulating antibody assay using porcine thyroid cells. Thyroid 20, 851\u2013856 (2010).","journal-title":"Thyroid"},{"key":"BFnrendo2013193_CR22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/ncpendmet0886","volume":"4","author":"RA Ajjan","year":"2008","unstructured":"Ajjan, R. A. & Weetman, A. P. Techniques to quantify TSH receptor antibodies. Nat. Clin. Pract. Endocrinol. Metab. 4, 461\u2013468 (2008).","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.autrev.2012.07.003","volume":"12","author":"R Tozzoli","year":"2012","unstructured":"Tozzoli, R., Bagnasco, M., Giavarina, D. & Bizzaro, N. TSH receptor autoantibody immunoassay in patients with Graves' disease: improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis. Autoimmun. Rev. 12, 107\u2013113 (2012).","journal-title":"Autoimmun. Rev."},{"key":"BFnrendo2013193_CR24","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1742-1241.2005.00545.x","volume":"59","author":"S Dasgupta","year":"2005","unstructured":"Dasgupta, S. & Savage, M. W. Evaluation of management of Graves' disease in district general hospital: achievement of consensus guidelines. Int. J. Clin. Pract. 59, 1097\u20131100 (2005).","journal-title":"Int. J. Clin. Pract."},{"key":"BFnrendo2013193_CR25","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/thy.2011.2106.ed3","volume":"21","author":"GJ Kahaly","year":"2011","unstructured":"Kahaly, G. J., Bartalena, L. & Heged\u00fcs, L. The American Association\/American Association of Clinical Endocrinologists guidelines for hyperthyroidism and other causes of thyrotoxicosis: a European perspective. Thyroid 21, 585\u2013591 (2011).","journal-title":"Thyroid"},{"key":"BFnrendo2013193_CR26","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1089\/thy.2011.0104","volume":"21","author":"EN Pearce","year":"2011","unstructured":"Pearce, E. N., Hennessey, J. V. & McDermott, M. T. New American Thyroid Association and American Association of Clinical Endocrinologists guidelines for thyrotoxicosis and other forms of hyperthyroidism: significant progress for the clinician and a guide to future research. Thyroid 21, 573\u2013576 (2011).","journal-title":"Thyroid"},{"key":"BFnrendo2013193_CR27","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1089\/thy.2011.2106.ed1","volume":"21","author":"S Yamashita","year":"2011","unstructured":"Yamashita, S., Amino, N. & Shong, Y. S. The American Thyroid Association and American Association of Clinical Endocrinologists hyperthyroidism and other causes of thyrotoxicosis guidelines: viewpoints from Japan and Korea. Thyroid 21, 577\u2013580 (2011).","journal-title":"Thyroid"},{"key":"BFnrendo2013193_CR28","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1210\/jcem-70-6-1518","volume":"70","author":"B Solomon","year":"1990","unstructured":"Solomon, B., Glinoer, D., Lagasse, R. & Wartofsky, L. Current trends in the management of Graves' disease. J. Clin. Endocrinol. Metab. 70, 1518\u20131524 (1990).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR29","first-page":"3","volume":"285","author":"D Glinoer","year":"1987","unstructured":"Glinoer, D., Hesch, D., Lagasse, R. & Laurberg, P. The management of hyperthyroidism due to Graves' disease in Europe in 1986. Results of an international survey. Acta Endocrinol. Suppl. (Copenh.) 285, 3\u201323 (1987).","journal-title":"Acta Endocrinol. Suppl. (Copenh.)"},{"key":"BFnrendo2013193_CR30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1507\/endocrj1954.36.299","volume":"36","author":"Y Nagayama","year":"1989","unstructured":"Nagayama, Y., Izumi, M. & Nagataki, S. The management of hyperthyroidism due to Graves' disease in Japan in 1988. Endocrinol. Jpn 36, 299\u2013314 (1989).","journal-title":"Endocrinol. Jpn"},{"key":"BFnrendo2013193_CR31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1089\/thy.1991.1.129","volume":"1","author":"L Wartofsky","year":"1991","unstructured":"Wartofsky, L.  et al. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid 1, 129\u2013135 (1991).","journal-title":"Thyroid"},{"key":"BFnrendo2013193_CR32","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1365-2265.2009.03623.x","volume":"72","author":"OE Okosieme","year":"2010","unstructured":"Okosieme, O. E., Chan, D., Price, S. A. & Lazarus, J. H. The utility of radioiodine uptake and thyroid scintigraphy in the diagnosis and management of hyperthyroidism. Clin. Endocrinol. (Oxf.) 72, 122\u2013127 (2010).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo2013193_CR33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2265.2009.03633.x","volume":"72","author":"JA Franklyn","year":"2010","unstructured":"Franklyn, J. A. What is the role of radioiodine uptake measurement and thyroid scintigraphy in the diagnosis and management of hyperthyroidism? Clin. Endocrinol. (Oxf.) 72, 11\u201312 (2010).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo2013193_CR34","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/ncpendmet0692","volume":"4","author":"F Bogazzi","year":"2008","unstructured":"Bogazzi, F. & Vitti, P. Could improved ultrasound and power Doppler replace thyroidal radioiodine uptake to assess thyroid disease? Nat. Clin. Pract. Endocrinol. Metab. 4, 70\u201371 (2008).","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR35","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/BF03349833","volume":"18","author":"P Vitti","year":"1995","unstructured":"Vitti, P.  et al. Thyroid blood flow evaluation by color-flow Doppler sonography distinguishes Graves' disease from Hashimoto's thyroiditis. J. Endocrinol. Invest. 18, 857\u2013861 (1995).","journal-title":"J. Endocrinol. Invest."},{"key":"BFnrendo2013193_CR36","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejrad.2007.03.015","volume":"65","author":"C Cappelli","year":"2008","unstructured":"Cappelli, C.  et al. The role of imaging in Graves' disease: a cost-effectiveness analysis. Eur. J. Radiol. 65, 99\u2013103 (2008).","journal-title":"Eur. J. Radiol."},{"key":"BFnrendo2013193_CR37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1530\/eje.0.1430339","volume":"143","author":"F Boi","year":"2000","unstructured":"Boi, F., Loy, M., Piga, M., Serra, A. & Mariotti, S. The usefulness of conventional and echo colour Doppler sonography in the differential diagnosis of toxic multinodular goitres. Eur. J. Endocrinol. 143, 339\u2013346 (2000).","journal-title":"Eur. J. Endocrinol."},{"key":"BFnrendo2013193_CR38","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1089\/thy.2005.15.1249","volume":"15","author":"S Kurita","year":"2005","unstructured":"Kurita, S.  et al. Measurement of thyroid blood flow area is useful for diagnosing the cause of thyrotoxicosis. Thyroid 15, 1249\u20131252 (2005).","journal-title":"Thyroid"},{"key":"BFnrendo2013193_CR39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2265.2007.02832.x","volume":"67","author":"H Ota","year":"2007","unstructured":"Ota, H.  et al. Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves' disease. Clin. Endocrinol. (Oxf.) 67, 41\u201345 (2007).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo2013193_CR40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4158\/EP.15.1.6","volume":"15","author":"KV Hari Kumar","year":"2009","unstructured":"Hari Kumar, K. V.  et al. Role of thyroid Doppler in differential diagnosis of thyrotoxicosis. Endocr. Pract. 15, 6\u20139 (2009).","journal-title":"Endocr. Pract."},{"key":"BFnrendo2013193_CR41","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1530\/eje.0.1400452","volume":"140","author":"F Bogazzi","year":"1999","unstructured":"Bogazzi, F.  et al. Thyroid vascularity and blood flow are not dependent on serum thyroid hormone levels: studies in vivo by color flow Doppler sonography. Eur. J. Endocrinol. 140, 452\u2013456 (1999).","journal-title":"Eur. J. Endocrinol."},{"key":"BFnrendo2013193_CR42","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1089\/thy.2006.0104","volume":"17","author":"MF Erdogan","year":"2007","unstructured":"Erdogan, M. F., Anil, C., Cesur, M., Baskal, N. & Erdogan, G. Color flow Doppler sonography for the etiologic diagnosis of hyperthyroidism. Thyroid 17, 223\u2013228 (2007).","journal-title":"Thyroid"},{"key":"BFnrendo2013193_CR43","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1586\/ecp.12.54","volume":"5","author":"RS Bahn","year":"2012","unstructured":"Bahn, R. S. Emerging pharmacotherapy for treatment of Graves' disease. Expert Rev. Clin. Pharmacol. 5, 605\u2013607 (2012).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"BFnrendo2013193_CR44","first-page":"29","volume":"6","author":"P Abraham","year":"2010","unstructured":"Abraham, P. & Acharya, S. Current and emerging treatment options for Graves' hyperthyroidism. Ther. Clin. Risk Manag. 6, 29\u201340 (2010).","journal-title":"Ther. Clin. Risk Manag."},{"key":"BFnrendo2013193_CR45","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2265.1992.tb02330.x","volume":"37","author":"AP Weetman","year":"1992","unstructured":"Weetman, A. P. How antithyroid drugs work in Graves' disease. Clin. Endocrinol. (Oxf.) 37, 317\u2013318 (1992).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo2013193_CR46","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra042972","volume":"352","author":"DS Cooper","year":"2005","unstructured":"Cooper, D. S. Antithyroid drugs. N. Engl. J. Med. 352, 905\u2013917 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2013193_CR47","first-page":"340","volume":"35","author":"F Bogazzi","year":"2012","unstructured":"Bogazzi, F., Tomisti, L., Bartalena, L., Aghini-Lombardi, F. & Martino, E. Amiodarone and the thyroid: a 2012 update. J. Endocrinol. Invest. 35, 340\u2013348 (2012).","journal-title":"J. Endocrinol. Invest."},{"key":"BFnrendo2013193_CR48","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1210\/jcem.87.2.8126","volume":"87","author":"FA Karlsson","year":"2001","unstructured":"Karlsson, F. A., Axelsson, O. & Melhus, H. Severe embriopathy and exposure to methimazole in early pregnancy. J. Clin. Endocrinol. Metab. 87, 947\u2013948 (2001).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR49","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ajmg.a.30418","volume":"132A","author":"N Foulds","year":"2005","unstructured":"Foulds, N., Walpole, I., Elmslie, F. & Mansour, S. Carbimazole embryopathy: an emerging phenotype. Am. J. Med. Genet. A 132A, 130\u2013135 (2005).","journal-title":"Am. J. Med. Genet. A"},{"key":"BFnrendo2013193_CR50","doi-asserted-by":"crossref","first-page":"E337","DOI":"10.1210\/jc.2010-0652","volume":"95","author":"M Clementi","year":"2010","unstructured":"Clementi, M.  et al. Treatment of hyperthyroidism in pregnancy and birth defects. J. Clin. Endocrinol. Metab. 95, E337\u2013E341 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR51","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1210\/jc.2009-2752","volume":"95","author":"AB Emiliano","year":"2010","unstructured":"Emiliano, A. B., Governale, L., Parks, M. & Cooper, D. S. Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008. J. Clin. Endocrinol. Metab. 95, 2227\u20132233 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR52","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1177\/106002800303700213","volume":"37","author":"JK Ruiz","year":"2003","unstructured":"Ruiz, J. K.  et al. Fulminant hepatic failure associated with propylthiouracil. Ann. Pharmacother. 37, 224\u2013228 (2003).","journal-title":"Ann. Pharmacother."},{"key":"BFnrendo2013193_CR53","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1089\/thy.2009.0169","volume":"19","author":"RS Bahn","year":"2009","unstructured":"Bahn, R. S.  et al. The role of propylthiouracil in the management of Graves' disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 19, 673\u2013674 (2009).","journal-title":"Thyroid"},{"key":"BFnrendo2013193_CR54","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1210\/jc.2009-0850","volume":"94","author":"DS Cooper","year":"2009","unstructured":"Cooper, D. S. & Rivkees, S. A. Putting propylthiouracil in perspective. J. Clin. Endocrinol. Metab. 94, 1881\u20131882 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR55","doi-asserted-by":"publisher","unstructured":"Abraham, P., Avenell, A., McGeoch, S. C., Clark, L. F. & Bevan, J. S. Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database of Systematic Reviews, Issue 1, Art no.: CD003420. \n                    http:\/\/dx.doi.org\/10.1002\/14651858.CD003420.pub4\n                    \n                  .","DOI":"10.1002\/14651858.CD003420.pub4"},{"key":"BFnrendo2013193_CR56","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199104043241403","volume":"324","author":"K Hashizume","year":"1991","unstructured":"Hashizume, K.  et al. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N. Engl. J. Med. 324, 947\u2013953 (1991).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2013193_CR57","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1530\/eje.1.01993","volume":"153","author":"P Abraham","year":"2005","unstructured":"Abraham, P., Avell, A., Park, C. M., Watson, W. A. & Bevan, J. S. A systematic review of drug therapy for Graves' hyperthyroidism. Eur. J. Endocrinol. 153, 489\u2013498 (2005).","journal-title":"Eur. J. Endocrinol."},{"key":"BFnrendo2013193_CR58","first-page":"337","volume":"87","author":"AP Weetman","year":"1994","unstructured":"Weetman, A. P., Pickerill, A. P., Watson, P., Chatterjee, V. K. & Edwards, O. M. Treatment of Graves' disease with the block-replace regimen of antithyroid drugs: the effect of treatment duration and immunogenetic susceptibility on relapse. Q. J. Med. 87, 337\u2013341 (1994).","journal-title":"Q. J. Med."},{"key":"BFnrendo2013193_CR59","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1530\/eje.1.01904","volume":"152","author":"F Azizi","year":"2005","unstructured":"Azizi, F., Atale, L., Hedayati, M., Mehrabi, Y. & Sheikholeslami, F. Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. Eur. J. Endocrinol. 152, 695\u2013701 (2005).","journal-title":"Eur. J. Endocrinol."},{"key":"BFnrendo2013193_CR60","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1530\/eje.1.02295","volume":"155","author":"P Laurberg","year":"2006","unstructured":"Laurberg, P. Remission of Graves' disease during anti-thyroid drug therapy. Time to reconsider the mechanism? Eur. J. Endocrinol. 155, 783\u2013786 (2006).","journal-title":"Eur. J. Endocrinol."},{"key":"BFnrendo2013193_CR61","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/BF03346433","volume":"31","author":"E Mazza","year":"2008","unstructured":"Mazza, E.  et al. Long-term follow-up of patients with hyperthyroidism due to Graves' disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study. J. Endocrinol. Invest. 31, 866\u2013872 (2008).","journal-title":"J. Endocrinol. Invest."},{"key":"BFnrendo2013193_CR62","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2265.1993.tb00970.x","volume":"38","author":"BL Solomon","year":"1993","unstructured":"Solomon, B. L., Wartofsky, L. & Burman, K. D. Adjunctive cholestyramine therapy for thyrotoxicosis. Clin. Endocrinol. (Oxf.) 38, 39\u201343 (1993).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo2013193_CR63","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-2265.2005.02249.x","volume":"62","author":"WC Tsai","year":"2005","unstructured":"Tsai, W. C.  et al. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism. Clin. Endocrinol. (Oxf.) 62, 521\u2013524 (2005).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo2013193_CR64","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/j.1365-2265.2009.03745.x","volume":"72","author":"K Takata","year":"2010","unstructured":"Takata, K.  et al. Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disase. Clin. Endocrinol. (Oxf.) 72, 845\u2013850 (2010).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo2013193_CR65","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00002018-199615010-00004","volume":"15","author":"L Bartalena","year":"1996","unstructured":"Bartalena, L., Bogazzi, F. & Martino, E. Adverse effects of thyroid hormone preparations and antithyroid drugs. Drug Saf. 15, 53\u201363 (1996).","journal-title":"Drug Saf."},{"key":"BFnrendo2013193_CR66","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1089\/thy.2008.0364","volume":"19","author":"K Takata","year":"2009","unstructured":"Takata, K.  et al. Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid 19, 559\u2013563 (2009).","journal-title":"Thyroid"},{"key":"BFnrendo2013193_CR67","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/thy.1997.7.369","volume":"7","author":"P Vitti","year":"1997","unstructured":"Vitti, P.  et al. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 7, 369\u2013375 (1997).","journal-title":"Thyroid"},{"key":"BFnrendo2013193_CR68","first-page":"1038","volume":"85","author":"A Allahabadia","year":"2000","unstructured":"Allahabadia, A., Daykin, J., Holder, R. L., Sheppard, M. C. & Franklyn, J. A. Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J. Clin. Endocrinol. Metab. 85, 1038\u20131042 (2000).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR69","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1530\/eje.0.1470583","volume":"147","author":"BG Nedrebo","year":"2002","unstructured":"Nedrebo, B. G.  et al. Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease. Eur. J. Endocrinol. 147, 583\u2013589 (2002).","journal-title":"Eur. J. Endocrinol."},{"key":"BFnrendo2013193_CR70","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1507\/endocrj.50.45","volume":"50","author":"T Kashiwai","year":"2003","unstructured":"Kashiwai, T.  et al. Practical treatment with minimum maintenance dose of antithyroid drugs for prediction of remission in Graves' disease. Endocr. J. 50, 45\u201349 (2003).","journal-title":"Endocr. J."},{"key":"BFnrendo2013193_CR71","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1210\/jc.2008-0966","volume":"93","author":"M Rotondi","year":"2008","unstructured":"Rotondi, M.  et al. The effects of pregnancy on subsequent relapse from Graves' disease after a successful course of antithyroid drug therapy. J. Clin. Endocrinol. Metab. 93, 3985\u20133988 (2008).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR72","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMct1007101","volume":"364","author":"DS Ross","year":"2011","unstructured":"Ross, D. S. Radioiodine therapy for hyperthyroidism. N. Engl. J. Med. 364, 542\u2013550 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2013193_CR73","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1365-2265.2007.03097.x","volume":"68","author":"B Vaidya","year":"2008","unstructured":"Vaidya, B., Williams, G. R., Abraham, P. & Pearce, S. H. S. Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists. Clin. Endocrinol. (Oxf.) 68, 814\u2013820 (2008).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo2013193_CR74","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1089\/thy.2011.0362","volume":"22","author":"S Sztal-Mazer","year":"2012","unstructured":"Sztal-Mazer, S.  et al. Evidence for higher success rates and successful treatment earlier in Graves' disease with higher radioactive iodine doses. Thyroid 22, 991\u2013995 (2012).","journal-title":"Thyroid"},{"key":"BFnrendo2013193_CR75","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1089\/thy.2010.0403","volume":"21","author":"JC Sisson","year":"2011","unstructured":"Sisson, J. C.  et al. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association. Thyroid 21, 335\u2013346 (2011).","journal-title":"Thyroid"},{"key":"BFnrendo2013193_CR76","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1136\/bmj.39114.670150.BE","volume":"334","author":"MA Walter","year":"2007","unstructured":"Walter, M. A.  et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomized controlled trials. BMJ 334, 514 (2007).","journal-title":"BMJ"},{"key":"BFnrendo2013193_CR77","first-page":"1073","volume":"87","author":"EK Alexander","year":"2002","unstructured":"Alexander, E. K. & Larsen, P. R. High dose of 131I therapy for the treatment of hyperthyroidism caused by Graves' disease. J. Clin. Endocrinol. Metab. 87, 1073\u20131077 (2002).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR78","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1530\/eje.0.1490485","volume":"149","author":"SJ Bonnema","year":"2003","unstructured":"Bonnema, S. J.  et al. Resumption of methimazole after 131I therapy of hyperthyroid diseases: effect on thyroid function and volume evaluated by a randomized clinical trial. Eur. J. Endocrinol. 149, 485\u2013492 (2003).","journal-title":"Eur. J. Endocrinol."},{"key":"BFnrendo2013193_CR79","first-page":"499","volume":"84","author":"F Bogazzi","year":"1999","unstructured":"Bogazzi, F.  et al. Comparison of radioiodine with radioiodine plus lithium in the treatment of Graves' hyperthyroidism. J. Clin. Endocrinol. Metab. 84, 499\u2013503 (1999).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR80","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1210\/jc.2009-1655","volume":"95","author":"F Bogazzi","year":"2010","unstructured":"Bogazzi, F.  et al. Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal. J. Clin. Endocrinol. Metab. 95, 201\u2013208 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR81","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1365-2265.2012.04385.x","volume":"77","author":"NM Martin","year":"2012","unstructured":"Martin, N. M.  et al. Adjuvant lithium improves the efficacy of radioactive iodine treatment in Graves' and toxic nodular disease. Clin. Endocrinol. (Oxf.) 77, 621\u2013627 (2012).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo2013193_CR82","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1056\/NEJM199803123381103","volume":"338","author":"JA Franklyn","year":"1998","unstructured":"Franklyn, J. A., Maisonneuve, P., Sheppard, M. C., Betteridge, J. & Boyle, P. Mortality after the treatment of hyperthyroidism with radioactive iodine. N. Engl. J. Med. 338, 712\u2013718 (1998).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2013193_CR83","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1210\/jc.2006-2321","volume":"92","author":"S Metso","year":"2007","unstructured":"Metso, S.  et al. Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J. Clin. Endocrinol. Metab. 92, 2190\u20132196 (2007).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR84","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1210\/jc.2007-0837","volume":"92","author":"M Vanderpump","year":"2007","unstructured":"Vanderpump, M. Cardiovascular and cancer mortality after radioiodine treatment of hyperthyroidism. J. Clin. Endocrinol. Metab. 92, 2033\u20132035 (2007).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR85","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1210\/jc.2012-3459","volume":"98","author":"K Boelaert","year":"2013","unstructured":"Boelaert, K., Maisonneuve, P., Torlinska, B. & Franklyn, J. A. Comparison of mortality in hyperthyroidism during the periods of treatment with thionamides and after radioiodine. J. Clin. Endocrinol. Metab. 98, 1869\u20131882 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR86","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/jnci\/83.15.1072","volume":"83","author":"LE Holm","year":"1991","unstructured":"Holm, L. E.  et al. Cancer risk after iodine-131 therapy for hyperthyroidism. J. Natl Cancer Inst. 83, 1072\u20131077 (1991).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrendo2013193_CR87","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jama.280.4.347","volume":"280","author":"E Ron","year":"1998","unstructured":"Ron, E.  et al. Cancer mortality following treatment for adult hyperthyroidism. JAMA 280, 347\u2013355 (1998).","journal-title":"JAMA"},{"key":"BFnrendo2013193_CR88","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1210\/jc.2003-031223","volume":"89","author":"CH Read Jr","year":"2004","unstructured":"Read, C. H. Jr, Tansey, M. J. & Menda, Y. A 36-year retrospective analysis of the efficacy and safety of radioiodine in treating young Graves' patients. J. Clin. Endocrinol. Metab. 89, 4229\u20134233 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR89","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/cncr.22635","volume":"109","author":"S Metso","year":"2007","unstructured":"Metso, S.  et al. Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer 109, 1972\u20131979 (2007).","journal-title":"Cancer"},{"key":"BFnrendo2013193_CR90","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/S0140-6736(98)12295-X","volume":"353","author":"JA Franklyn","year":"1999","unstructured":"Franklyn, J. A., Maisonneuve, P., Sheppard, M., Betteridge, J. & Boyle, P. Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet 353, 2111\u20132115 (1999).","journal-title":"Lancet"},{"key":"BFnrendo2013193_CR91","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1210\/jc.2006-1239","volume":"92","author":"SA Rivkees","year":"2007","unstructured":"Rivkees, S. A. & Dinauer, C. An optimal treatment for pediatric Graves' disease is radioiodine. J. Clin. Endocrinol. Metab. 92, 797\u2013800 (2007).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR92","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJM199206253262603","volume":"326","author":"L Tallstedt","year":"1992","unstructured":"Tallstedt, L.  et al. Occurrence of ophthalmopathy after treatment for hyperthyroidism. N. Engl. J. Med. 326, 1733\u20131738 (1992).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2013193_CR93","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199801083380201","volume":"338","author":"L Bartalena","year":"1998","unstructured":"Bartalena, L.  et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N. Engl. J. Med. 338, 73\u201378 (1998).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2013193_CR94","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1210\/jc.2009-0747","volume":"94","author":"F Tr\u00e4isk","year":"2009","unstructured":"Tr\u00e4isk, F.  et al. Thyroid-associated ophthalmopathy after treatment for hyperthyroidism with antithyroid drugs or iodine-131. J. Clin. Endocrinol. Metab. 94, 3700\u20133707 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR95","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1365-2265.2008.03279.x","volume":"69","author":"SH Acharya","year":"2008","unstructured":"Acharya, S. H.  et al. Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review. Clin. Endocrinol. (Oxf.) 69, 943\u2013950 (2008).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo2013193_CR96","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM198911163212001","volume":"321","author":"L Bartalena","year":"1989","unstructured":"Bartalena, L.  et al. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine treatment for hyperthyroidism. N. Engl. J. Med. 321, 1349\u20131352 (1989).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2013193_CR97","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1210\/jc.2009-2130","volume":"95","author":"A Lai","year":"2010","unstructured":"Lai, A.  et al. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves' orbitopathy: a retrospective cohort study. J. Clin. Endocrinol. Metab. 95, 1333\u20131337 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR98","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1530\/eje.0.1300494","volume":"130","author":"L Tallstedt","year":"1994","unstructured":"Tallstedt, L., Lundell, G., Blomgren, H. & Bring, J. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? Eur. J. Endocrinol. 130, 494\u2013497 (1994).","journal-title":"Eur. J. Endocrinol."},{"key":"BFnrendo2013193_CR99","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1210\/jc.2005-0507","volume":"90","author":"P Perros","year":"2005","unstructured":"Perros, P., Kendall-Taylor, P., Neoh, C., Frewin, S. & Dickinson, J. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves' ophthalmopathy. J. Clin. Endocrinol. Metab. 90, 5321\u20135323 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR100","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1210\/jc.2005-1553","volume":"90","author":"L Bartalena","year":"2005","unstructured":"Bartalena, L. Glucocorticoids for Graves' orbitopathy: how and when. J. Clin. Endocrinol. Metab. 90, 5497\u20135499 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR101","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/EJE-07-0666","volume":"158","author":"L Bartalena","year":"2008","unstructured":"Bartalena, L.  et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur. J. Endocrinol. 158, 273\u2013285 (2008).","journal-title":"Eur. J. Endocrinol."},{"key":"BFnrendo2013193_CR102","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1006\/jsre.2000.5875","volume":"90","author":"TK Palit","year":"2000","unstructured":"Palit, T. K., Miller, C. C. 3rd & Miltenburg, D. M. The efficacy of thyroidectomy for Graves' disease: a meta-analysis. J. Surg. Res. 90, 161\u2013165 (2000).","journal-title":"J. Surg. Res."},{"key":"BFnrendo2013193_CR103","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1007\/s00268-012-1617-x","volume":"36","author":"M Annerbo","year":"2012","unstructured":"Annerbo, M., St\u00e5lberg, P. & Hellman, P. Management of Graves' disease is improved by total thyroidectomy. World J. Surg. 36, 1943\u20131946 (2012).","journal-title":"World J. Surg."},{"key":"BFnrendo2013193_CR104","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1089\/thy.2011.0153","volume":"22","author":"A Al-Adhami","year":"2012","unstructured":"Al-Adhami, A., Craig, W. & Krukowski, Z. H. Quality of life after surgery for Graves' disease: comparison of those having surgery intended to preserve thyroid function with those having ablative surgery. Thyroid 22, 494\u2013500 (2012).","journal-title":"Thyroid"},{"key":"BFnrendo2013193_CR105","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jamcollsurg.2009.03.025","volume":"209","author":"H In","year":"2009","unstructured":"In, H.  et al. Treatment options for Graves disease: a cost-effectiveness analysis. J. Am. Coll. Surg. 209, 170\u2013179 (2009).","journal-title":"J. Am. Coll. Surg."},{"key":"BFnrendo2013193_CR106","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1245\/s10434-012-2606-x","volume":"20","author":"BM Genovese","year":"2013","unstructured":"Genovese, B. M., Noureldine, S. I., Gleeson, E. M., Tufano, R. P. & Kandil, E. What is the best definitive treatment for Graves' disease? A systematic review of the existing literature. Ann. Surg. Oncol. 20, 660\u2013667 (2013).","journal-title":"Ann. Surg. Oncol."},{"key":"BFnrendo2013193_CR107","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1089\/thy.2006.0141","volume":"17","author":"S Grodski","year":"2007","unstructured":"Grodski, S., St\u00e5lberg, P., Robinson, B. G. & Delbridge, L. W. Surgery versus radioiodine therapy as definitive management for Graves' disease: the role of patient preference. Thyroid 17, 157\u2013160 (2007).","journal-title":"Thyroid"},{"key":"BFnrendo2013193_CR108","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00268-008-9479-y","volume":"32","author":"P Miccoli","year":"2008","unstructured":"Miccoli, P.  et al. Minimally invasive video-assisted thyroidectomy for benign thyroid disease: an evidence-based review. World J. Surg. 32, 1333\u20131340 (2008).","journal-title":"World J. Surg."},{"key":"BFnrendo2013193_CR109","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00268-007-9375-x","volume":"32","author":"A Sasaki","year":"2008","unstructured":"Sasaki, A.  et al. Endoscopic thyroidectomy by the breast approach: a single institution's 9-year experience. World J. Surg. 32, 381\u2013385 (2008).","journal-title":"World J. Surg."},{"key":"BFnrendo2013193_CR110","first-page":"93","volume":"2","author":"J Lee","year":"2013","unstructured":"Lee, J. & Chung, W. Y. Robotic surgery for thyroid disease. Eur. Thyroid J. 2, 93\u2013101 (2013).","journal-title":"Eur. Thyroid J."},{"key":"BFnrendo2013193_CR111","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jamcollsurg.2007.11.023","volume":"206","author":"JA Sosa","year":"2008","unstructured":"Sosa, J. A., Mehta, P. J., Wang, T. S., Boudourakis, L. & Roman, S. A. A population-based study of outcomes from thyroidectomy in aging Americans: at what cost? J. Am. Coll. Surg. 206, 1097\u20131105 (2008).","journal-title":"J. Am. Coll. Surg."},{"key":"BFnrendo2013193_CR112","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1210\/jc.2007-0229","volume":"92","author":"Y Erbil","year":"2007","unstructured":"Erbil, Y.  et al. Effect of lugol solution on thyroid gland blood flow microvessel density in the patients with Graves' disease. J. Clin. Endocrinol. Metab. 92, 2182\u20132189 (2007).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR113","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1046\/j.1365-2265.1999.00843.x","volume":"51","author":"C Marcocci","year":"1999","unstructured":"Marcocci, C.  et al. The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case\u2013control study. Clin. Endocrinol. (Oxf.) 51, 503\u2013508 (1999).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo2013193_CR114","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1530\/EJE-07-0450","volume":"158","author":"P Laurberg","year":"2008","unstructured":"Laurberg, P.  et al. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur. J. Endocrinol. 158, 69\u201375 (2008).","journal-title":"Eur. J. Endocrinol."},{"key":"BFnrendo2013193_CR115","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/bjs.8660","volume":"99","author":"M Barczinsky","year":"2012","unstructured":"Barczinsky, M., Konturek, A., Hubalewska-Dydejczyk, A., Golkowski, F. & Nowak, W. Randomized clinical trial of bilateral subtotal thyroidectomy versus total thyroidectomy for Graves' disease with a 5-year follow-up. Br. J. Surg. 99, 515\u2013522 (2012).","journal-title":"Br. J. Surg."},{"key":"BFnrendo2013193_CR116","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.amjsurg.2011.10.010","volume":"204","author":"J Jin","year":"2012","unstructured":"Jin, J., Sandoval, V., Lawless, M. E., Sehgal, A. R. & McHenry, C. R. Disparity in the management of Graves' disease observed at an urban county hospital: a decade-long experience. Am. J. Surg. 204, 199\u2013202 (2012).","journal-title":"Am. J. Surg."},{"key":"BFnrendo2013193_CR117","first-page":"33","volume":"17","author":"EH Sidib\u00e9","year":"2007","unstructured":"Sidib\u00e9, E. H. Thyr\u00e9opathies en Afrique subsaharienne [French]. Cahiers Sant\u00e9 17, 33\u201339 (2007).","journal-title":"Cahiers Sant\u00e9"},{"key":"BFnrendo2013193_CR118","first-page":"163","volume":"6","author":"A Mithal","year":"1993","unstructured":"Mithal, A., Shah, A. & Kumar, S. The management of Graves' disease by Indian thyroidologists. Natl Med. J. India 6, 163\u2013166 (1993).","journal-title":"Natl Med. J. India"},{"key":"BFnrendo2013193_CR119","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s00268-006-0572-9","volume":"31","author":"VP Pradeep","year":"2007","unstructured":"Pradeep, V. P.  et al. Safety and efficacy of surgical management of hyperthyroidism: 15-year experience from a tertiary care center in a developing country. World J. Surg. 31, 306\u2013312 (2007).","journal-title":"World J. Surg."},{"key":"BFnrendo2013193_CR120","first-page":"603","volume":"53","author":"R Sankar","year":"2005","unstructured":"Sankar, R., Sekhri, T., Sripathy, G., Walia, R. P. & Jain, S. K. Radioactive iodine therapy in Graves' hyperthyroidism: a prospective study from a tertiary referral centre in north India. J. Assoc. Physicians India 53, 603\u2013606 (2005).","journal-title":"J. Assoc. Physicians India"},{"key":"BFnrendo2013193_CR121","first-page":"124","volume":"45","author":"ME Ahmed","year":"1993","unstructured":"Ahmed, M. E., ElWasila, A. A., Sanhouri, M. & Yagi, K. Surgical management of toxic goiter in Khartoum. Trop. Geogr. Med. 45, 124\u2013125 (1993).","journal-title":"Trop. Geogr. Med."},{"key":"BFnrendo2013193_CR122","first-page":"516","volume":"62","author":"SY Akossou","year":"2001","unstructured":"Akossou, S. Y.  et al. Problems in the management of thyrotoxicosis in Black Africa: the Tongolese experience [French]. Ann. Endocrinol. (Paris) 62, 516\u2013520 (2001).","journal-title":"Ann. Endocrinol. (Paris)"},{"key":"BFnrendo2013193_CR123","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1445-5994.2000.tb00856.x","volume":"30","author":"JP Walsh","year":"2000","unstructured":"Walsh, J. P. Management of Graves' disease in Australia. Aust. NZ J. Med. 30, 559\u2013566 (2000).","journal-title":"Aust. NZ J. Med."},{"key":"BFnrendo2013193_CR124","first-page":"251","volume":"104","author":"HC Ford","year":"1991","unstructured":"Ford, H. C., Delahunt, J. W. & Feek, C. M. The management of Graves' disease in New Zealand: results of national survey. NZ Med. J. 104, 251\u2013252 (1991).","journal-title":"NZ Med. J."},{"key":"BFnrendo2013193_CR125","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1210\/jc.2010-2329","volume":"96","author":"L Bartalena","year":"2011","unstructured":"Bartalena, L. The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy. J. Clin. Endocrinol. Metab. 96, 592\u2013599 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"Suppl. 2","key":"BFnrendo2013193_CR126","first-page":"185","volume":"121","author":"MF Prummel","year":"1989","unstructured":"Prummel, M. F.  et al. Amelioration of eye changes of Graves' ophthalmopathy by achieving euthyroidism. Acta Endocrinol. (Copenh.) 121 (Suppl. 2), 185\u2013189 (1989).","journal-title":"Acta Endocrinol. (Copenh.)"},{"key":"BFnrendo2013193_CR127","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1001\/archinte.1990.00390170124027","volume":"150","author":"MF Prummel","year":"1990","unstructured":"Prummel, M. F.  et al. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Arch. Intern. Med. 150, 1098\u20131101 (1990).","journal-title":"Arch. Intern. Med."},{"key":"BFnrendo2013193_CR128","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1530\/eje.1.02201","volume":"155","author":"P Perros","year":"2006","unstructured":"Perros, P.  et al. A questionnaire survey on the management of Graves' orbitopathy in Europe. Eur. J. Endocrinol. 155, 207\u2013211 (2006).","journal-title":"Eur. J. Endocrinol."},{"key":"BFnrendo2013193_CR129","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/BF03346732","volume":"34","author":"S Zang","year":"2011","unstructured":"Zang, S., Ponto, K. A., Pitz, S. & Kahaly, G. J. Dose of intravenous steroids and therapy outcome in Graves' orbitopathy. J. Endocrinol. Invest. 34, 876\u2013880 (2011).","journal-title":"J. Endocrinol. Invest."},{"key":"BFnrendo2013193_CR130","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","volume":"97","author":"L Bartalena","year":"2012","unstructured":"Bartalena, L.  et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy. J. Clin. Endocrinol. Metab. 97, 4454\u20134463 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR131","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1210\/jc.2012-2758","volume":"97","author":"ML Tanda","year":"2012","unstructured":"Tanda, M. L. & Bartalena, L. Efficacy and safety of orbital radiotherapy for Graves' orbitopathy. J. Clin. Endocrinol. Metab. 97, 3857\u20133865 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR132","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1089\/thy.2010.0181","volume":"21","author":"L Elbers","year":"2011","unstructured":"Elbers, L., Mourits, M. & Wiersinga, W. Outcome of very long-term treatment with antithyroid drugs in Graves' hyperthyroidism associated with Graves' orbitopathy. Thyroid 21, 279\u2013283 (2011).","journal-title":"Thyroid"},{"key":"BFnrendo2013193_CR133","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1089\/thy.2011.0039","volume":"21","author":"P Laurberg","year":"2011","unstructured":"Laurberg, P., Berman, D. C., Andersen, S. & B\u00fclow Pedersen, I. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy. Thyroid 21, 951\u2013956 (2011).","journal-title":"Thyroid"},{"key":"BFnrendo2013193_CR134","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1089\/105072503322240004","volume":"13","author":"M Moleti","year":"2003","unstructured":"Moleti, M.  et al. Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of Graves' ophthalmopathy. Thyroid 13, 653\u2013658 (2003).","journal-title":"Thyroid"},{"key":"BFnrendo2013193_CR135","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1210\/jc.2006-1800","volume":"92","author":"F Menconi","year":"2007","unstructured":"Menconi, F.  et al. Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids. J. Clin. Endocrinol. Metab. 92, 1653\u20131658 (2007).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR136","doi-asserted-by":"crossref","first-page":"E44","DOI":"10.1210\/jc.2011-2077","volume":"97","author":"M Leo","year":"2012","unstructured":"Leo, M.  et al. Outcome of Graves' orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial. J. Clin. Endocrinol. Metab. 97, E44\u2013E48 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013193_CR137","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s12020-011-9559-x","volume":"41","author":"A De Bellis","year":"2012","unstructured":"De Bellis, A.  et al. Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study. Endocrine 41, 320\u2013326 (2012).","journal-title":"Endocrine"}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2013.193","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2013.193.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2013.193.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:41:35Z","timestamp":1684467695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrendo.2013.193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,15]]},"references-count":137,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["BFnrendo2013193"],"URL":"https:\/\/doi.org\/10.1038\/nrendo.2013.193","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,15]]}}}